Zobrazení zdroje stránky Lindgaardkramer2831

Objective To examine the risk of self-harm in rheumatological conditions METHODS Retrospective cohort study using data from the Clinical Practice Research Datalink. Patients with ankylosing spondylitis, fibromyalgia, osteoarthritis or rheumatoid arthritis were identified between 1990-2016 and matched to patients without these conditions. Incident self-harm was defined by medical record codes following a rheumatological diagnosis. Incidence rates (per 10,000 person-years(PY)) were reported for each condition, both overall and year-on-year(2000-2016). Cox regression analysis determined risk (hazard ratios(HR), 95% confidence interval(CI)) of self-harm for each rheumatological cohort compared to the matched unexposed cohort. Initial crude analysis was subsequently adjusted and stratified by age and gender. Due to non-proportionality over time, osteoarthritis was also stratified by disease duration( less then 1 year, ≥1- less then 5 years, ≥5- less then 10 years, ≥10 years). Results Incidence of self-harm was highest in patients with fibromyalgia (25.12 (95%CI 22.45,28.11) per 10,000 PY) and lowest for osteoarthritis (6.48 (6.20, 6.76)). There was a crude association with each rheumatological condition and self-harm, except for ankylosing spondylitis. Though attenuated, these associations remained after adjustment for fibromyalgia (HR 2.06(95%CI 1.60,2.65)), rheumatoid arthritis (1.59(1.20,2.11)) and osteoarthritis (1- less then 5years 1.12 (1.01,1.24); ≥5- less then 10 years 1.35 (1.18,1.54)). Age and gender were weak effect modifiers for these associations. Conclusions Primary care patients with fibromyalgia, osteoarthritis or rheumatoid arthritis (but not ankylosing spondylitis) are at increased risk of self-harm compared to people without these rheumatological conditions. Clinicians need to be aware of the potential for self-harm in patients with rheumatological conditions (particularly fibromyalgia), explore mood and risk with them, and offer appropriate support and management.Background The long-term trajectory of depressive symptoms has a heterogeneous pattern. [https://www.selleckchem.com/products/sb290157-tfa.html buy SB290157] Identifying factors associated with different trajectories and outcomes may have important theoretical and clinical implications. This study explored patterns of depressive symptom trajectory from adolescence to adulthood, and their relationship with subsequent psychiatric disorders. Method A sample of 816 participants (58.8% girls; M = 16.58 years old at baseline, SD = 1.21) from a large community sample were interviewed four times during adolescence and adulthood. Depressive symptoms were also assessed. Symptom trajectory identification was based on latent class mixed modeling. Logistic regression was used for predicting emotional and drug use disorder over age 30. Results Three trajectories of depressive symptoms were identified "decreasing symptom" (decreasing trajectory of symptoms; 15.1% of participants), "increasing symptom" (initially decreasing pattern of symptoms and then increasing; 6.1% of participants), and "normative symptom" (consistently low symptom levels; 78.8% of participants). Predictors of the increasing symptom trajectory were high level of loneliness and state anxiety, presence of an emotional disorder, and low involvement in physical exercise at baseline. This trajectory membership predicted the development of anxiety disorders over age 30. Predictors of the decreasing symptom class were being female and high level of worry at baseline. Conclusions Long-term trajectories of depressive symptoms are heterogeneous, with each trajectory having different predictors and are associated with different outcomes during adulthood.Basic treatment of atopic dermatitis (AD) associates topical corticosteroids (TCS) during flares and daily moisturizing to restore epidermal barrier. The TOPICOP® questionnaire measuring fear, beliefs and reluctance to TCS use showed an average level of TCS phobia of 44% (35%-58%).1 Therapeutic patient education (TPE) did not affect fear suggesting a possible role of caregivers in TCS phobia.2 We focused on the risk factors of parental TCS phobia.MicroRNAs (miRNAs) are an important class of non-coding small RNAs that regulate the expression of target genes through mRNA cleavage or translational inhibition. Previous studies have revealed their roles in regulating seed dormancy and germination in model plants such as Arabidopsis thaliana, rice (Oryza sativa), and maize (Zea mays). However, the miRNA response to exogenous gibberellic acid (GA) and abscisic acid (ABA) during seed germination in maize has yet to be explored. In this study, small RNA libraries were generated and sequenced from embryos treated with GA, ABA, or double-distilled water as control. A total of 247 miRNAs (104 known and 143 novel ones) were identified, of which 45 known and 53 novel miRNAs were differentially expressed in embryos in the different treatment groups. Seventy-four (37 up-regulated and 37 down-regulated) and 55 (23 up-regulated and 32 down-regulated) miRNAs were expressed in response to GA and to ABA, respectively, and a total of 18 known and 38 novel miRNAs displayed differential expression between the GA- and ABA-treated groups. Using bioinformatics tools, we predicted the target genes of the differentially expressed miRNAs. GO enrichment and KEGG pathway analysis of these targets showed that miRNAs differentially expressed in our samples affect genes encoding proteins involved in the peroxisome, ribosome, and plant hormonal signalling pathways. Our results indicated that miRNA-mediated gene expression influences the GA and ABA signalling pathways during seed germination.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel single-stranded RNA virus that has gripped humanity all over. It affects primarily the respiratory system, but is not limited to it, causing widespread involvement of many organ systems. The cases are still rising at an exponential rate and manifold trials are on to test different agents with the hope for potential limitation of spread and control of symptoms. Various classes of drugs have been tried; some with moderate success while many are yet to be proven to be of definite benefit. We have observed that the drugs used in dermatology practice are featured in more than a few of such studies. Here, we wish to highlight the ones that we are familiar with, which has featured at some point, in the management of this very challenging pandemic.